ERBB2 and breast carcinoma: Increased glycolytic activity is also explained by the greater activity of some of the enzymes in the pathway, such as hexokinase 2, which is overexpressed in breast cancer [24,25] and whose inhibition in transgenic mice that develop breast cancer after overexpression of ErbB2/Neu delays tumor development [24].